First Bank & Trust Sells 4,494 Shares of Gilead Sciences, Inc. $GILD

First Bank & Trust lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,342 shares of the biopharmaceutical company’s stock after selling 4,494 shares during the period. Gilead Sciences makes up 0.7% of First Bank & Trust’s portfolio, making the stock its 27th biggest position. First Bank & Trust’s holdings in Gilead Sciences were worth $4,367,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at $215,000. Summit Financial LLC lifted its holdings in shares of Gilead Sciences by 7.5% during the first quarter. Summit Financial LLC now owns 20,893 shares of the biopharmaceutical company’s stock valued at $2,341,000 after acquiring an additional 1,459 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Gilead Sciences by 1.9% in the 1st quarter. Ameriprise Financial Inc. now owns 1,356,212 shares of the biopharmaceutical company’s stock valued at $151,976,000 after purchasing an additional 25,659 shares in the last quarter. Finally, Compound Planning Inc. grew its holdings in shares of Gilead Sciences by 179.0% in the 1st quarter. Compound Planning Inc. now owns 23,193 shares of the biopharmaceutical company’s stock worth $2,599,000 after purchasing an additional 14,881 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Citigroup raised their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Mizuho lifted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. UBS Group raised Gilead Sciences to a “hold” rating in a report on Thursday, December 4th. Finally, The Goldman Sachs Group raised their price target on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.54.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the sale, the chief executive officer directly owned 571,203 shares in the company, valued at $72,280,027.62. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $124.29 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a 50 day simple moving average of $122.35 and a 200 day simple moving average of $116.16. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm has a market cap of $154.20 billion, a P/E ratio of 19.27, a P/E/G ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.